About Amytrx Therapeutics
Amytrx Therapeutics is a private company based in Nashville, Tennessee. It has reported $4,915,000 raised in four offerings on Form D since August 2015. Its chief executive is Matthew Gonda.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 15, 2023 | Jan 31, 2024 | $725,000of $6.0M target | 7 | $103K | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 16, 2020 | Aug 12, 2020 | $3,590,000of $12.0M target | 34 | $105K | EquityRule 506(b) | Form D ↗ |
| Jul 17, 2017 | Sep 5, 2017 | $0of $2.0M target | 0 | — | EquityRule 506(b) | Form D ↗ |
| Jun 26, 2015 | Aug 4, 2015amended Jul 1, 2016 | $600,000of $4.5M target | 7 | $85,714 | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Total, four offerings | $4,915,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Amytrx Therapeutics's Form D filed Jan 31, 2024.
MG
Matthew Gonda
President and CEO, director
LG
Lawrence Greer
Director
SJ
Satish Joshi
Director
MH
Michael Howell
Director
DC
Dennis Carlo
Director
RP
Raymond Pirtle
Director
Earlier filings also listed Thomas Andrews (director, last listed Aug 2020), Daniel Pirtle (director, last listed Aug 2020), Daniel Canale (director, last listed Aug 2020) and Jerry Kluft (director, last listed Jul 2016).